Why don't they put it in millions instead of thousands, it
sounds better. Nice pressie anyway...
R&D Tax Incentive Receipt 22nd December 2016: Analytica Ltd (ASX: ALT), is pleased to announce the receipt of $1,157k from the Australian Taxation Office under the Research and Development incentive related to the financial year to 30th June 2016. The Research and Development Tax Incentive is an initiative of the federal government to assist small companies to invest in essential research and development to be internationally competitive with new innovative products. This incentive is a welcome boost to our research funding and Analytica is grateful for the support. The major focus of Analytica is to develop best in class, non-pharmaceutical, non-surgical treatment for pelvic floor muscle disorders, to dramatically improve women’s quality of life. Over the last 12 months, case studies have been published in peer reviewed urological journals, app enhancements launched to track fluids and leakage, and our V2 clinical trial has reached a point where interim analysis is underway. Analytica continues to invest in R&D to develop the version 3 product and the PeriCoach Data system. The PeriCoach is more than the medical device. Powerful data analysis tools are also in development turning personal health data into global insights for areas of clinical procedure, product development opportunities, marketing tactics and product efficacy. Analytica is a focused R&D company, but not all expenditure is eligible for the R&D incentive. The incentive’s intent is to encourage Australian investment in fundamental research. Analytica’s investment in global markets is centred upon growing the user database and paring with science to provide insights into women’s pelvic health. Published clinical papers, case studies and presentations are demonstrating favourable results and are in front of the key specialists of the industry. Analytica continues to build a compellin
ALT Price at posting:
0.6¢ Sentiment: Hold Disclosure: Held
